Observation of the therapeutic effect and prognosis analysis of Yiqijiebiao prescription for the treatment of children with influenza B

Abstract

To observe the efficacy of Yiqijiebiao prescription in treating children with influenza B infection (flu). A total of 120 children with influenza B infection who were treated at the Traditional Chinese Medicine (TCM) Clinic of Tianjin Children's Hospital from October to December 2019 were enrolled. According to different treatments, the children were divided into Yiqijiebiao prescription treatment group and Western medicine treatment control group, with 60 cases in each group. Yiqijiebiao prescription treatment group was orally given Yiqijiebiao prescription plus and minus treatment (composition: perilla leaf, kudzu root, Bupleurum, Qing Pinellia, Scutellaria baicalensis Georgi each 6 g, tangerine peel, nepeta panicle, Divaricate Saposhniovia root, praecupura, almond, ginseng, platycodon, roasted licorice each 4 g, add plaster and cooked rhubarb for dry stools, add pre-bait, honey loquat leaves for severe cough, add Angelica dahurica and flos magnoliae for runny nose), take 1 dose a day, twice a day; Western medicine treatment control group was orally given Ribavirin, 10 mg/kg each time, 3 times a day. After 7 days of treatment, the changes in clinical symptoms, laboratory results and clinical efficacy of the two groups were observed, and the changes in prognostic indexes of the two groups were analyzed. The numbers of children with normal body temperature and improved or partially improved symptoms such as cough, sore throat, and runny nose in the Yiqijiebiao prescription treatment group were significantly higher than those in the control group (normal body temperature: 49 cases vs. 44 cases, cough relieved: 33 cases vs. 25 cases, sore throat relieved: 27 cases vs. 23 cases, runny nose relieved: 47 cases vs. 42 cases, all P < 0.05). The numbers of children whose nasopharyngeal swabs with influenza B virus antibody (IBV-Ag) turned negative and serum amyloid A (SAA) and C-reactive protein (CRP) in the normal reference value range (< 10 mg/L) were significantly higher than those in Western medicine treatment control group (IBV-Ag negative: 36 cases vs. 31 cases, SAA in the normal reference value range: 49 cases vs. 46 cases, CRP in the normal reference value range: 50 cases vs. 46 cases, all P < 0.05). The total effective rate of Yiqijiebiao prescription treatment group after treatment was significantly higher than that of control group [81.67% (49/60) vs. 75.00% (45/60), P < 0.05]. The numbers of children with constipation, loss of appetite and diarrhea in the Yiqijiebiao prescription treatment group were significantly less than those in the control group (constipation: 11 cases vs. 14 cases, loss of appetite: 8 cases vs. 11 cases, diarrhea: 6 cases vs. 8 cases, all P < 0.05). Yiqijiebiao prescription can significantly improve the clinical symptoms and laboratory results of children with influenza B infection and increase the total effective rate, and have a definite effect.